📢 Pharmidex at the 36th RSC BMCS Spring Symposium on Medicinal Chemistry 🧪
April 22, 2025

This annual symposium is a key event in the medicinal chemistry calendar, bringing together researchers and industry professionals to discuss cutting-edge advances in drug discovery.


Our team will be available to discuss how Pharmidex’s integrated services can support the development of novel therapeutics from early discovery through to candidate selection.


📍 Location: Hatfield, UK

 📅 Date: 24th April 2025

 🔗 www.pharmidex.com, https://lnkd.in/eZdCsd4M


We look forward to engaging with the scientific community and exploring new opportunities for collaboration. Visit our stand or contact [email protected]. 


See you there!

#HatfieldMedChem25 #Pharmidex #BMCS2025 #MedicinalChemistry #DrugDiscovery #ADME #Bioanalysis #CNS #DMPK #PharmaceuticalSciences #oncology #respiratory #ContractResearchOrganisation #CRO #Preclinical #Networking #Collaboration

🚀 Pharmidex at the R&D Society Life Science Workshop!

June 11, 2025
Pharmidex team are delighted to participate in workshop on "Re-shaping UK life science commercialisation strategy" organised by The Research and Development Society on Wednesday 11th June, at Mereside, Alderley Park. If you are attending, please linkup with our colleague Mo Alavijeh who will be delighted to meet you. Jamie Phadke , Alderley Park #UKlifescience https://lnkd.in/e6uKsRcN

🔬 Pharmidex at the 4th RSC Anglo-Nordic Medicinal Chemistry Symposium

June 10, 2025
Martin Barrett , Head of Business Development, will attend the symposium on 10–13 June 2025 at Hotel Comwell Borupgaard, Denmark. The event gathers top European scientists to discuss drug discovery. Martin looks forward to connecting with academia, CROs, and pharma to explore collaborations and showcase Pharmidex’s services from in silico to in vivo pharmacology. Attending? Let’s connect! 🔗 https://lnkd.in/ev7TW7WG

🔬 Pharmidex is proud to contribute to new research!

June 10, 2025
We’re excited to announce our involvement in the recent publication: "Anti-Inflammatory Activity of Ensifentrine: A Novel, Selective Dual Inhibitor of PDE3 and PDE4" 📄 https://pubmed.ncbi.nlm.nih.gov/40245851/ 📄 https://www.pharmidex.com/publications-by-pharmidex Dr. Radhakrishnan Venkatasamy , our Senior Scientist in autoinflammatory and immune diseases, co-authored this study highlighting Ensifentrine’s anti-inflammatory potential. This reflects Pharmidex’s commitment to advancing therapies through expert science and collaboration.
More Posts